NCT00739037终止1 期
A Randomized, Single Dose, Placebo-Controlled, 2 Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAZ 417 in Cerebrospinal Fluid, When Administered Orally to Subjects With Alzheimer's Disease
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2008年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- This study is the measurement of a biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD).
研究概览
简要总结
The primary purpose of this study is to assess biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD). This study will also consider another biomarker amyloid beta peptide 42 (Ab42) in Cerebrospinal Fluid in subjects with Alzheimer Disease and assess the safety, tolerability and pharmacokinetic profile of PAZ-417 in both plasma and Cerebrospinal Fluid in these subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
A
Placebo Comparator
干预措施: Placebo (Drug)
B
Experimental
干预措施: PAZ-417 (Drug)
结局指标
主要结局
This study is the measurement of a biomarker known as amyloid beta peptide 40 (Ab40) in Cerebrospinal Fluid (CSF), following a single oral dose of PAZ-417 in subjects with Alzheimer Disease (AD).
时间窗: 6 days
次要结局
- To measure both amyloid beta peptide 42 (Ab42) and PAZ-417 in both plasma and CSF and assess safety using the results of physical examinations, vital sign measurements, ECGs, cardiac telemetry, standard laboratory tests and collection of AES.(6 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Evaluating GSI-953 in Healthy Young and Alzheimer's PatientsAlzheimer DiseaseNCT00479219Wyeth is now a wholly owned subsidiary of Pfizer17
进行中（未招募）
不适用
CUPAB studyMild cognitive impairment, Alzheimer's Disease (AD) , non- AD, Cognitively unimpaired individualsJPRN-jRCTs032200043akamura Akinori200
已完成
2 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge TestAcute Cannabinoid IntoxicationNCT05282797Anebulo Pharmaceuticals154
招募中
不适用
Clinical research to evaluate beta-amyloid deposition in the brain of patients with Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB)JPRN-UMIN000047904Juntendo University School of Medicine60
已完成
不适用
Amyloid Beta-peptide 1-40 and Alzheimer's DiseaseAlzheimer DiseaseNCT02770482CHU de Reims204